- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Melanoma | Clinical
A Decade of Transformation in Melanoma Treatments
May 23, 2022
Ongoing and proposed melanoma research will naturally continue to evaluate new treatment types.
Study of ATL001 Plus ICI Therapy Now Enrolling Patients with Metastatic Melanoma
May 09, 2022
The phase 1/2 THETIS clinical trial is actively recruiting patients with metastatic melanoma to be treated with the investigation combination of ATL001 and an immune checkpoint inhibitor.
Spartalizumab With Dabrafenib and Trametinib Shows Modest Efficacy in BRAF V600+ Metastatic Melanoma
May 05, 2022
The phase 3 COMBI-i trial demonstrated that spartalizumab plus dabrafenib and trametinib has modest efficacy in BRAF V600-positive metastatic melanoma, but no progression-free survival benefit when compared with dabrafenib and trametinib alone.
Melanoma Monday: A Review of the MSLT-II Trial and Completion Lymph Node Dissection
May 02, 2022
Katherine E. Poruk, MD, reviews the use of complete axillary lymph node dissection and the Multicenter Selective Lymphadenectomy Trial II for Melanoma Monday.
FDA Grants Orphan Drug Designation to Darovasertib for Uveal Melanoma Treatment
May 02, 2022
With an FDA orphan drug designation for the treatment of patients with uveal melanoma, darovasertib is being actively investigated in a phase 1/2 clinical trial.
MATINS Trial Results Will Be Shared at EADO
April 28, 2022
Results from the melanoma cohort the MATINS trial will be shared at the 18th Congress of the European Association of Dermato-Oncology.
Combo of BO-112 and Pembrolizumab Elicits Response in Advanced Melanoma
April 21, 2022
For advanced melanoma that is resistant to anti–PD-1 therapies, the addition of BO-112 to pembrolizumab appears to be effective and safe.
Delays in BRAF Test Results Affect Quality of Care, Therapeutic Options in Melanoma
April 13, 2022
Barriers to improving BRAF testing turnaround time in patients with melanoma have been identified in a retrospective analysis of real-world data collected in Canada.
Sotigalimab/Pembrolizumab Combo Shows Safety and Broad Immune Activity in Metastatic Melanoma
April 13, 2022
Response were observed with the combination of sotigalimab and pembrolizumab in patients with metastatic melanoma treated in a phase 1/2 study.
Nivolumab With PD-L1/IDO Peptide Vaccine Shows Efficacy in Metastatic Melanoma
April 08, 2022
According to a phase 1/2 study, nivolumab plus PD-L1/IDO peptide vaccine may be effective for the treatment of patients with metastatic melanoma.